News

Avella Newsroom

January 1, 1970|
Avella CEO Letter Regarding Direct and Indirect Remuneration (DIR) Fees
March 29, 2017| CATEGORIES: Specialty Pharmacy , Press Release

Calling on Centers for Medicare & Medicaid Services to Curb Below-Cost Reimbursement to Specialty Pharmacies by Pharmaceutical Benefit Managers, to Clarify Medicare Definitions, & Promote Accurate & Responsible Reimbursement

Direct & Indirect Remuneration (DIR) fees erode access to vital clinical services & breakthrough drugs for the most vulnerable Americans, increasing costs across the board & negatively impacting seniors & their caregivers, pharmacies, & taxpayers that fund Medicare

Last week, Frier Levitt, LLC; and the National Association of Specialty Pharmacy (NASP) published a white paper describing the advent and negative consequences of Direct and Indirect Remuneration (DIR) fees. America’s seniors need the Centers for Medicare and Medicaid Services (CMS) to take immediate action to stop Pharmaceutical Benefits Managers (PBMs) from levying inappropriate, unreasonable and unsustainable DIR fees on specialty pharmacies.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe